Latest From Sysmex Corp.
Start-Up Spotlight: Sight Diagnostics’ Imaging Technology Allows Accurate Diagnostics With Small Blood Samples
The US FDA recently cleared Sight’s Olo analyzer to run complete blood counts on samples as small as two drops. The company is currently marketing Olo to hospital labs in the US but hopes to eventually earn a CLIA waiver so Olo can be marketed to smaller physician practices and pharmacies and used for other common blood-based diagnostics.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Oxford Gene Technology has appointed its former head of R&D, John Anson, as CEO and brought in a new head of regulatory affairs, Paul Kenny, as the company shifts resources to the molecular diagnostics market.
Molecular diagnostics company genedrive has signed a distribution agreement with Sysmex Corporation to distribute its CE-marked HepC (HCV) ID kit and Genedrive platform in the Europe, Middle East and Africa. The Japanese group is the first commercial partner for genedrive's hepatitis C test for decentralized resource-limited settings.
In Vitro Diagnostics
- Hematology, Coagulation
- Urine-based Testing
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Sysmex Corp.
- Senior Management
- Hisashi Ietsugu, Chmn. & CEO
- Contact Info
Phone: (81) 78-265-0500
Kobe, Hyogo, 651-0073
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.